[Asia Economy Reporter Oh Ju-yeon] On the 10th, Samsung Biologics' stock price surged by over 8%, showing strong performance.
On the same day, Samsung Biologics announced that it signed a letter of intent for a contract worth 441.8 billion KRW for the contract manufacturing of biopharmaceuticals with a U.S.-based pharmaceutical company.
Following this news, Samsung Biologics' stock price quickly surpassed the 500,000 KRW mark.
As of 9:58 AM, Samsung Biologics' stock price was trading at 517,000 KRW, up 8.05% compared to the previous trading day.
After falling to the 360,000 KRW range on the 19th of last month, Samsung Biologics has since hovered around the 400,000 KRW range.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
